PUMA BIOTECHNOLOGY INC

PBYINASDAQ

🏆 #2411 by market capEarnings Nov 5US Equity

$8.77▲ $0.08 (+0.92%)

🌙 After hours$8.43▼ 3.88%Regular close · extended-hours price shown

1h—

24h▲ 0.9%

7d▲ 9.5%

14d▲ 12.5%

30d▲ 8.4%

1y▲ 80.1%

🏦Market Cap

$446M

Small Cap

📈Revenue Growth (YoY)

-0.9%

Declining

📊Gross Margin

74.8%

High

💵FCF Margin

17.8%

Healthy

⚖️P/S Ratio

1.9x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $8.69 – $8.91
52-Week Range: $4.30 – $9.40
Volume: $6.10B
Avg Volume: $6.92B
Shares Outstanding: 50.9M
Next Earnings: Oct 6, 2026

Fundamentals Snapshot

Annual Revenue: $228M
Last Q Revenue: $57M
P/E Ratio: 16.4
P/S Ratio: 1.9x
EPS (TTM): $0.52
Dividend Yield: 0.00%

Why Investors Own PBYI

✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 26% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$228M▲ +26.8% YoY

Gross Margin (TTM)

77.8%▲ +2.2% YoY

Operating Income (TTM)

$47M▲ +26.8% YoY

Free Cash Flow (TTM)

$60M▲ +26.8% YoY

About PUMA BIOTECHNOLOGY INC

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.

🦦